Israel-based oral drug delivery systems developer Oramed Pharmaceuticals has received an approval for a patent, titled 'Methods and Compositions for Oral Administrations of Proteins', from the State Intellectual Property Office of the People's Republic of China.
With the new patent in China, the company's approved patents totals eight, while 27 patents are in pending.
Oramed Pharmaceuticals CEO Nadav Kidron noted the company's platform technology in the oral delivery of proteins applies to numerous treatment markets in geographies around the globe.
"China is a very important market for both our ORMD-0801 and ORMD-0901 technologies. As an innovative company committed to discovery, we are pleased to see our IP portfolio expand," Kidron added.
The company has also received the patent, which covers a core concept of the company's oral delivery technology, in New Zealand and South Africa.
Oramed is currently advancing with clinical trials of ORMD-0801, an orally ingestible insulin capsule, for the treatment of type 1 diabetes.
